MOLECULAR PARTNERS ADS/1
MOLECULAR PARTNERS ADS/1
Hinterlegungsschein · US60853G1067 · MOLN · A3CSB5 (XNAS)
Übersicht
3,41 EUR
2,26 % 0,08 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
09.06.2025 16:17

Aktuelle Kurse von MOLECULAR PARTNERS ADS/1

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
MOLN
USD
09.06.2025 16:17
3,89 USD
3,80 USD
+2,26 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 8,24 % -6,70 % -20,56 % -36,16 % -10,04 % -80,31 %

Firmenprofil zu MOLECULAR PARTNERS ADS/1 Hinterlegungsschein

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Unternehmensdaten

Name MOLECULAR PARTNERS ADS/1
Firma Molecular Partners AG
Symbol MOLN
Website https://www.molecularpartners.com
Heimatbörse XNAS Frankfurt
WKN A3CSB5
ISIN US60853G1067
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Patrick Amstutz Ph.D.
Marktkapitalisierung 147 Mio
Land Schweiz
Währung EUR
Mitarbeiter 0,2 T
Adresse Wagistrasse 14, 8952 Schlieren
IPO Datum 2021-06-16

Ticker Symbole

Name Symbol
Frankfurt 6ML0.F
NASDAQ MOLN

Weitere Aktien

Investoren die MOLECULAR PARTNERS ADS/1 die halten, haben auch folgende Aktien im Depot:
CRED.SUISSE GRP16/26 REGS
CRED.SUISSE GRP16/26 REGS Anleihe
INCOME CONTINGENT STUDENT LOANS 2 (2007-2009) PLC CLASS B ASSET BKD IL NTS 24/07/58
INCOME CONTINGENT STUDENT LOANS 2 (2007-2009) PLC CLASS B ASSET BKD IL NTS 24/07/58 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025